Lifeboat Foundation

Following a marathon EU summit in Brussels, national leaders this morning agreed to a €1.8 trillion, 7-year budget and pandemic recovery fund that will spend €81 billion on Horizon Europe, the main EU research program. That’s far less than what researchers had hoped for—and €13.5 billion less than a proposal 2 months ago from the European Commission, the EU executive arm.

An €81 billion budget for Horizon Europe disappoints researchers.

🤔

In October 2019, the Johns Hopkins Center for Health Security hosted a pandemic tabletop exercise called Event 201 with partners, the World Economic Forum and the Bill & Melinda Gates Foundation. Recently, the Center for Health Security has received questions about whether that pandemic exercise predicted the current novel coronavirus outbreak in China. To be clear, the Center for Health Security and partners did not make a prediction during our tabletop exercise. For the scenario, we modeled a fictional coronavirus pandemic, but we explicitly stated that it was not a prediction. Instead, the exercise served to highlight preparedness and response challenges that would likely arise in a very severe pandemic. We are not now predicting that the nCoV-2019 outbreak will kill 65 million people. Although our tabletop exercise included a mock novel coronavirus, the inputs we used for modeling the potential impact of that fictional virus are not similar to nCoV-2019.

COVID19 has no treatment, yet people have been treating disease for centuries. How is that possible? Are people now just using the wrong treatment?

Colds, accompanied by coughing, running nose, sore throat, bronchitis, sinus infections, eardrum infections and infectious flu, do not occur only during the cold and wet seasons, but all through the year, according to your disposition. Himalayan Pink Salt applications not only help to relieve the cold (Infectious flu and sorethroat), but are also excellent preventive therapies.

TOKYO – Although scientists know many of the underlying symptoms which trigger Alzheimer’s disease, a cure remains elusive. Now, a new study suggests that oxytocin, a hormone best known for promoting feelings of love and wellbeing, may reverse some of the damage the degenerative illness causes.

Alzheimer’s disease is a progressive brain disease causing the continuous deterioration of mental functions. Its primary symptoms include severely impaired thinking, memory loss, and confusion.

One of the primary culprits in Alzheimer’s is a protein known as amyloid β (Aβ). Researchers say Aβ clumps together to form plaques around neurons in the brain. These plaque build-ups disrupt normal neuron function and triggers the degeneration.

Extremophiles like the bacterium D. radiodurans that can withstand levels of radiation thousands of times what most animals can, are able to help us make vaccines faster, cheaper and safer. They use special molecular protectors to shield their repair proteins but not their DNA or RNA.

Scientists at Columbia University in New York screened antibodies from 40 Covid-19 patients and identified 61 types from five individuals that effectively wiped out coronavirus. Among them were nine that displayed “exquisite potency” for neutralising the pathogen.

Tests on cells showed that the antibodies killed off the virus, while experiments with hamsters revealed that an infusion of one of the more potent antibodies protected the animals from disease. “It shut off infectious virus completely in the lung tissue of the hamsters we treated,” said David Ho, a professor of medicine at Columbia who led the research.

“We specifically isolated very potent antibodies that can be mass produced and then administered,” Ho said. “We would assume that these could be used to prevent or treat Sars-Cov-2. We’d be looking to treat early in the course of infection, particularly those at risk of developing severe disease such as the elderly and those with underlying illness.”

Did you know there was a natural treatment for herpes “that has no treatment”. People have been treating disease for centuries. Just because something is not approved does not mean it does not work, it only means it is not approved. Even corruption can stall the approval process.

TMR5 (Zedupex^TM) is a product of a Kenyan medicinal plant, prepared as a lyophilized extract and a cream. The products have been evaluated for preclinical safety and efficacy in suitable in vitro and in vivo systems of herpes infections. Herpes is a viral infection affecting over 60% of the sub-Saharan Africa young adult population. It is caused by two similar viruses, HSV-1 and HSV-2 which share 50% gene sequence homology. The infection in a major cause of genital ulcer disease, associated with increased risks of HIV acquisition and transmission. The aim is to develop TMR5 as an alternative anti-herpes agent, this being necessitated by increased resistance to available drugs and the cost of the drug of choice, acyclovir, in the region. Using the trypan blue exclusion test, plaque inhibition and viral yield reduction assays for assessment of cytotoxicity (CC₅₀) and efficacy (EC₅₀), and Mice and guinea pig cutaneous and genital HSV infection models respectively following oral and topical treatments, TMR5 exhibited no cytotoxicity in mammalian cell lines with a wide therapeutic index (CC₅₀ ≥ 58.5 ± 4.6µg/ml). An EC₅₀ of ≤ 14.7 ± 3.7µg/ml for both wild type and resistant strains of HSV was realised in plaque and viral yield assays. Oral (250 mg/kg) and topical (10% cream) administrations exhibited significant delay in onset of infections, hindered progression of infection to lethal forms with increased mean survival times and low mortality in both mice and guinea pig models. No acute toxicity has been realised at the therapeutic concentrations. TMR5 has demonstrated a high potential as an anti-herpes agent and arrangements are presently underway to evaluate its efficacy and safety in human clinical trials. A pilot production scheme supported by the National Commission for Science, Technology and Innovation (NCSTI) of Kenya has been undertaken as means of developing TMR5 as an alternative management therapy for herpes infections.

The U.S. will pay Pfizer and biotech firm BioNTech $1.95 billion to produce and deliver 100 million doses of their Covid-19 vaccine if it proves safe and effective, the companies announced Wednesday.

It was the largest such deal between the government and companies racing to develop a coronavirus vaccine.

Under the agreement, the U.S. can acquire 500 million additional doses, the Department of Health and Human Services said. Germany-based BioNTech and Pfizer are jointly developing four potential vaccines.

An invention may turn one of the most widely used materials for biomedical applications into wearable devices to help monitor heart health.

A team from Purdue University developed self-powered wearable triboelectric nanogenerators (TENGs) with polyvinyl alcohol (PVA)-based contact layers for monitoring cardiovascular health. TENGs help conserve mechanical energy and turn it into power.

The Purdue team’s work is published in the journal Advanced Materials.